Targeted radiopharmaceuticals for clinical imaging and therapy have the potential to revolutionize preclinical research and patient care for many diseases, including neurodegeneration, metabolic illnesses, and cancer. My research aims at developing new technologies and techniques, including novel radiochemical methodologies, accessible high-throughput experimentation techniques, and advanced process optimization workflows to bring radiopharmaceutical development and production in the data science age. Leveraging these approaches will drastically increase the rate and efficiency with which we can get bleeding edge radiopharmaceutical concepts to the people who need them most.